Black Titan Corp (NASDAQ:BTTC) Sees Significant Decline in Short Interest

Black Titan Corp (NASDAQ:BTTC) was the recipient of a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 4,312 shares, a decrease of 82.4% from the May 14th total of 24,499 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 33,269 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Armistice Capital LLC bought a new position in shares of Black Titan during the fourth quarter worth approximately $840,000. HRT Financial LP bought a new position in shares of Black Titan during the fourth quarter worth approximately $28,000. Renaissance Technologies LLC bought a new position in shares of Black Titan during the fourth quarter worth approximately $26,000. Finally, Marex Group plc bought a new position in shares of Black Titan during the fourth quarter worth approximately $84,000.

Black Titan Stock Performance

Black Titan stock opened at $0.90 on Wednesday. The company has a market cap of $9.69 million, a PE ratio of -0.31 and a beta of 1.20. Black Titan has a twelve month low of $0.86 and a twelve month high of $39.00. The firm has a 50-day moving average of $1.24.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.